Optimizing Piperacillin-Tazobactam Infusion Schedules for Pneumonia Treatment in Patients Aged 65 to 100

What this Trial Is About

Researchers are evaluating the infusion regimens of the antibiotic Piperacillin-Tazobactam in elderly patients aged 65 and older who have pneumonia. This study focuses on comparing two different dosing schedules to understand which infusion method better achieves the desired drug concentration for treating pneumonia effectively in this age group. The goal is to provide evidence that can guide clinical practice for this vulnerable population. The study compares two treatment groups one receiving Piperacillin Sodium and Tazobactam Sodium for Injection Bonda 4.5g every 8 hours with each infusion lasting 3 hours, and the other receiving the same drug every 6 hours with each infusion lasting 4 hours. These different infusion schedules are being assessed to determine their impact on drug levels in the body and clinical outcomes. Participants will receive the assigned infusion regimen and undergo monitoring during the study period. Researchers will evaluate the clinical improvement rate after 3 months as the primary outcome. Secondary outcomes include the pharmacokineticpharmacodynamic target attainment within 2 days, 28-day mortality rate, 7-day microbiological clearance rate, and the length of hospital and ICU stays up to 24 weeks. This comprehensive assessment will help understand the effectiveness and safety of the infusion regimens in elderly pneumonia patients.

A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia